Skip to main content
. Author manuscript; available in PMC: 2022 Aug 23.
Published in final edited form as: Mol Imaging Biol. 2020 Sep 3;23(1):109–116. doi: 10.1007/s11307-020-01536-2

Table 2:

Adverse Events

Dose cohort Total patients (n=81) Number of AEsa (n=6) Gradeb Toxicity Serious adverse event Relationship to Panitumumab-IRDye800CW

<0.5 mg/kg 12 1 (8.3%) 1 Prolonged QTc No Possible
0.5–1.0 mg/kg 35 1 (2.9%) 1 Prolonged QTc No Probable
1.0–1.5 mg/kg 12 1 (8.3%) 2 Hypertension No Possible
1.5–2.0 mg/kg 12 - - - - -
2.0–3.0 mg/kg 10 1 (10%) 1 Presyncope No Possible
1 (10%) 1 Prolonged QTc No Possible
1 (10%) 1 Vomiting No Possible
a

AE = adverse event

b

Grade 1 = mild, Grade 2 = moderate